The REAC-TAVI Trial: Is There a Need for More Potent Antithrombotic Strategy in TAVR?

JACC Cardiovasc Interv. 2019 Apr 22;12(8):802-803. doi: 10.1016/j.jcin.2019.02.004.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Aortic Valve / surgery
  • Aortic Valve Stenosis / surgery*
  • Fibrinolytic Agents
  • Humans
  • Transcatheter Aortic Valve Replacement*
  • Treatment Outcome

Substances

  • Fibrinolytic Agents